Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mary Butcher

Family Medicine Columbus, OH Medical Doctor

NPI 1366540379 CMS profile 288545

41 S High St Ste 25, Columbus, OH 43215

Open in the dashboard

General payments

$2,836

184 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mary Butcher of Columbus, OH is reported in the CMS Open Payments database as having received $2,836 across 184 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $583 30
2024 General $644 37
2023 General $431 29
2022 General $455 30
2021 General $308 28
2020 General $175 12
2019 General $240 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mary Butcher
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Mary Butcher were reported at $583. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Mary Butcher Family Medicine median Middle half National median
2019 $240 $150 $41–$543 $163
2020 $175 $120 $32–$415 $114
2021 $308 $137 $35–$551 $132
2022 $455 $137 $37–$512 $149
2023 $431 $149 $42–$545 $160
2024 $644 $156 $44–$560 $164
2025 $583 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. CutisPharma, Inc. $753 42 payments
  2. AbbVie, Inc. $339 28 payments
  3. Arbor Pharmaceuticals, Inc. $240 17 payments
  4. AstraZeneca Pharmaceuticals LP $226 14 payments
  5. Kowa Pharmaceuticals America, Inc. $196 15 payments
  6. Merck Sharp & Dohme Corporation $181 11 payments
  7. IBSA Pharma Inc. $175 11 payments
  8. Lilly USA, LLC $103 6 payments
  9. Novo Nordisk Inc $96 7 payments
  10. Paratek Pharmaceuticals, Inc. $93 5 payments
  11. Other $432 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,836 184 payments
Products named General payments · program years 2019–2025
  1. EDARBYCLOR Cardiovascular $531 27 payments
  2. Edarbyclor Cardiology/Vascular Diseases $363 26 payments
  3. Livalo $196 15 payments
  4. DIFICID $181 11 payments
  5. Tirosint $175 11 payments
  6. Licart $147 9 payments
  7. Bystolic $129 10 payments
  8. AIRSUPRA $123 7 payments
  9. MOUNJARO $103 6 payments
  10. ZEPBOUND $103 6 payments
  11. Other $1,551 103 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 48 drugs

Part D claims

1,693

Median for Family Practice: 1,826

Drug cost

$174,158

Median for Family Practice: $120,094

Branded share of claims

25.3%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 46 $50,876
Ozempic Semaglutide Brand 50 $46,785
Januvia Sitagliptin Phosphate Brand 16 $25,983
Xarelto Rivaroxaban Brand 17 $17,029
Synthroid Levothyroxine Sodium Brand 81 $7,648
Janumet Sitagliptin Phos/Metformin Hcl Brand 12 $7,500
Nebivolol Hcl Generic 36 $3,590
Rosuvastatin Calcium Generic 222 $2,357
Atorvastatin Calcium Generic 104 $896
Telmisartan Generic 28 $781

The 10 drugs with the highest cost, of 48 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EDARBYCLOR
  • CutisPharma, Inc. $330
$330 — —
NUZYRA
  • Paratek Pharmaceuticals, Inc. $60
$60 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $35
$35 — —
DIFICID
  • Merck Sharp & Dohme Corporation $34
$34 — —
UNITHROID
  • Amneal Pharmaceuticals LLC $29
$29 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

184 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record